BAY 2416964 + pembrolizumab

This combination therapy involves **BAY 2416964**, a small molecule oral inhibitor of the **Aryl Hydrocarbon Receptor (AhR)**, and **pembrolizumab**, a monoclonal antibody immune checkpoint inhibitor targeting PD-1 (Programmed cell death protein 1). BAY 2416964 acts by antagonizing AhR, thereby reversing immune suppression within the tumor microenvironment and promoting pro-inflammatory immune responses, specifically enhancing cytotoxic T cell activity and reducing immunosuppressive cell populations. Pembrolizumab, known by the brand name Keytruda, blocks PD-1 to further stimulate T cell-mediated antitumor activity. This combination is under clinical investigation for advanced solid tumors, notably head and neck, lung, and bladder cancers, with the aim of overcoming tumor immune resistance and enhancing antitumor efficacy compared to monotherapy[1][2][4][6][7][8].

Other names

BAY2416964 + KeytrudaBAY2416964 + pembrolizumab